Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Research & Development (2016 - 2025)

ImmunityBio (IBRX) has disclosed Research & Development for 12 consecutive years, with $400000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Research & Development fell 20.0% to $400000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $53.5 million, a 72.69% decrease, with the full-year FY2024 number at $3.3 million, down 98.58% from a year prior.
  • Research & Development was $400000.0 for Q1 2025 at ImmunityBio, down from $1.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $79.3 million in Q1 2023 to a low of $400000.0 in Q1 2025.
  • A 5-year average of $37.1 million and a median of $50.2 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 405.08% in 2021, then crashed 99.37% in 2024.
  • ImmunityBio's Research & Development stood at $51.8 million in 2021, then increased by 21.89% to $63.1 million in 2022, then fell by 15.72% to $53.2 million in 2023, then crashed by 97.74% to $1.2 million in 2024, then plummeted by 66.67% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Research & Development are $400000.0 (Q1 2025), $1.2 million (Q4 2024), and $800000.0 (Q3 2024).